Drug intelligence / Profile preview

SOBIN-AD

Development stage: Preclinical
Lead developer: AltPep

Overview

SOBIN-AD is a proprietary program developed by AltPep Corporation aimed at targeting and neutralizing toxic soluble oligomers associated with Alzheimer’s disease. The program is part of AltPep's broader efforts to develop early disease-modifying treatments and detection tools for amyloid diseases. While the SOBA-AD assay, also from AltPep, is a diagnostic blood test designed to detect these toxic oligomers for early diagnosis of Alzheimer’s disease, the SOBIN-AD program specifically focuses on therapeutic intervention by neutralizing these molecular triggers before they lead to plaque formation and neurodegeneration. The mechanism involves selective binding or neutralization of soluble amyloid-beta oligomers implicated in the pathogenesis of Alzheimer's disease[1][2].

Brand names: SOBIN-AD
Other names: SOBIN-AD

Targets

Amyloid-β protofibrils

Beyond the preview

Go deeper on SOBIN-AD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SOBIN-AD.

Explore the full profile